5:54 PM
 | 
Sep 10, 2013
 |  BC Extra  |  Top Story

EC approves first biosimilar mAb

The European Commission approved the first biosimilar mAb -- Inflectra/ Remsima infliximab from Celltrion Inc. (KOSDAQ:068270) and partner Hospira Inc. (NYSE:HSP) to treat multiple inflammatory conditions. Hospira plans to start launching the biosimilar of autoimmune drug

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >